Table 2.

Urine concentration of KIM-1 and NGAL in patients with UPJO (study group and control 1) and healthy controls (control 2).

Exama/group	uKIM-1 (ng/ml)	uKIM/cr. (ng/mg cr.)	uNGAL (ng/ml)	uNGAL/cr. (ng/mg cr.)
Exam A (voided urine before pyeloplasty)	1.35 A, b (0.96–6.76)	3.13 A, b (0.6–10.73)	8.38 A, b (3.3–55.22)	23.66 A, b (2.04–60.35)
Exam B (urine samples from affected pelvis during surgery)	1.37 b (0.27–5.3)	3.42 B, b (0.19–9.59)	12.43 A, b (1.78–100.0)	38.48 B, b (1.5–131.23)
Exam C (voided urine 3 months after surgery)	1.41 b (0.6–4.88)	1.73 A, b (0.48–6.94)	3.37 b (1.09–55.3)	5.62 a (2.15–25.78)
Control 1 (children had suspected but not confirmed UPJO)	0.84 b (0.23–2.71)	1.04 (0.18–5.69)	3.94 b (1.23–12.15)	3.8 a (0.9–44.77)
Control 2 (healthy children)	0.37 (0.15–1.82)	0.58 (0.15–3.01)	1.64 (0.25–5.77)	2.31 (0.27–16.27)

uKIM-1, Urinary kidney injury molecule-1; uNGAL, urinary neutrophil gelatinase-associated lipocalin; cr., creatinine; UPJO, ureteropelvic junction obstruction

Values are given as the median with the range given in parenthesis

p ^A < 0.05 to control 1, p ^a < 0.05 to control 2; p ^B < 0.01 to control 1, p ^b < 0.01 to control 2